Biotech Values

[vinmantoo]

Micro,

Onxx is now profitable from Nexavar, but the profitabilty has been held down by trial expenses due to attempts to expand Nexavar indications. Approval in one or more indications can dramatically improve profitability. The Japanese deal recouped about 40% of the entire Proteolix deal that brought Carfilzomib to Onxx, so I expect some nice cash coming from selling rights to the rest of Asia. I do expect Onxx to partner in Europe. The agreement with Bayer changed on Dec 20 , such that Onxx stated any buyout now will not come at the Nexavar profits. Someone also posted that the deal with Bayer changes so that Bayer is now responsible for trial expenses, although I can't verify the latter.

I must say you have been pretty negative towards Onxx for sometime and that hasn't been very accurate. I still don't understand your view now.